|
20 Jul 2021 |
Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose
|
|
20 Jul 2021 |
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
|
|
20 Jul 2021 |
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
|
|
20 Jul 2021 |
U.S. FDA Grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 Vaccine
|
|
19 Jul 2021 |
Almirall receives European Commission approval of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis
|
|
19 Jul 2021 |
Cytokinetics Announces Positive Topline Results of Redwood-HCM
|
|
19 Jul 2021 |
Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
|
|
19 Jul 2021 |
Samsung Bioepis Initiates Phase 3 Clinical Trial for SB17, Proposed Biosimilar to Stelara (Ustekinumab)
|
|
19 Jul 2021 |
U.S. FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)
|
|
19 Jul 2021 |
Ubix Therapeutics kicks off IND-enabling studies of Bruton’s tyrosine kinase degrader
|
|
17 Jul 2021 |
GC LabCell and GC Cell to Merge, Creating a Premier Cell Therapy Company
|
|
17 Jul 2021 |
Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes
|
|
16 Jul 2021 |
Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck
|
|
16 Jul 2021 |
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors
|
|
16 Jul 2021 |
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
|
|
16 Jul 2021 |
Celltrion’s Monoclonal Antibody Treatment for COVID-19, regdanvimab (CT-P59), Demonstrates Strong Neutralising Activity Against Delta Variant
|
|
16 Jul 2021 |
Status on FDA Advisory Committee vote on roxadustat in anaemia of chronic kidney disease
|
|
16 Jul 2021 |
Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)
|
|
16 Jul 2021 |
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC
|
|
15 Jul 2021 |
Shape Therapeutics Secures $112 Million in Series B Financing to Advance Breakthrough RNA Technology Platforms to Democratize Gene Therapy
|
